TRANSPLANTATION AND CELLULAR ENGINEERING
CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients
Article first published online: 15 AUG 2012
© 2012 American Association of Blood Banks
Volume 53, Issue 5, pages 1024–1032, May 2013
How to Cite
Varmavuo, V., Mäntymaa, P., Silvennoinen, R., Nousiainen, T., Kuittinen, T. and Jantunen, E. (2013), CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion, 53: 1024–1032. doi: 10.1111/j.1537-2995.2012.03848.x
- Issue published online: 9 MAY 2013
- Article first published online: 15 AUG 2012
- Received for publication April 18, 2012; revision received June 29, 2012, and accepted July 3, 2012.
BACKGROUND: Cyclophosphamide (CY) combined with granulocyte–colony-stimulating factor (G-CSF) is commonly used to mobilize stem cells in multiple myeloma (MM). Plerixafor may also be used with G-CSF in patients who mobilize poorly or it may be added to chemomobilization to boost mobilization. Limited data are available on graft content collected after various mobilization methods.
STUDY DESIGN AND METHODS: Blood grafts collected from 21 MM patients were retrospectively analyzed. We analyzed CD34+ subclasses and lymphocyte subsets from cryopreserved grafts collected on the next morning after plerixafor injection in nine MM patients mobilized with G-CSF with (n = 5) or without preceding CY (n = 4). As controls we had the first collections from 12 MM patients mobilized with low-dose CY with G-CSF.
RESULTS: The proportion of the most primitive stem cells (CD34+CD133+CD38–) from all CD34+ cells in the graft was higher in the plerixafor-treated patients but there was no significant difference in the total number of these cells. The numbers of CD19+ B lymphocytes and natural killer cells were higher in patients collected after G-CSF plus plerixafor when compared to the patients mobilized with CY plus G-CSF. Early engraftment after high-dose melphalan was comparable between the groups.
CONCLUSION: Plerixafor appears to have effects on blood stem cell graft composition in myeloma patients. A higher number of grafts should be evaluated in regard to cellular content and longer follow-up of the patients is needed to evaluate the potential clinical impact of graft content.